Godrej Khambatta
Bristol-Myers Squibb (Germany)(DE)
Publications by Year
Research Areas
PI3K/AKT/mTOR signaling in cancer, Melanoma and MAPK Pathways, Mast cells and histamine, Quinazolinone synthesis and applications, Cancer, Lipids, and Metabolism
Most-Cited Works
- → A Cereblon Modulator (CC-220) with Improved Degradation of Ikaros and Aiolos(2017)287 cited
- → Characterization and Kinetic Mechanism of Catalytic Domain of Human Vascular Endothelial Growth Factor Receptor-2 Tyrosine Kinase (VEGFR2 TK), a Key Enzyme in Angiogenesis(1998)74 cited
- → Optimization of a Series of Triazole Containing Mammalian Target of Rapamycin (mTOR) Kinase Inhibitors and the Discovery of CC-115(2015)72 cited
- → CC-223, a Potent and Selective Inhibitor of mTOR Kinase: In Vitro and In Vivo Characterization(2015)52 cited
- → Discovery of the c-Jun N-Terminal Kinase Inhibitor CC-90001(2021)37 cited
- → Discovery of Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor CC-223(2015)32 cited
- → Discovery of the Selective Protein Kinase C-θ Kinase Inhibitor, CC-90005(2021)8 cited
- → 459 Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation(2014)2 cited
- → 337 The Discovery and Preclinical Characterization of CC-223, a Novel mTOR Kinase Inhibitor Under Clinical Investigation(2012)2 cited
- → Data from CC-223, a Potent and Selective Inhibitor of mTOR Kinase: <i>In Vitro</i> and <i>In Vivo</i> Characterization(2023)